Tobiasson M

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Tobiasson M, Pandzic T, Illman J, ..., Dybedal I, Hellström-Lindberg E

J Clin Oncol 42 (12) 1378-1390 [2024-04-20; online 2024-01-17]

Clinical Genomics Uppsala [Collaborative]

Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation.

Dimitriou M, Mortera-Blanco T, Tobiasson M, ..., Woll PS, Jacobsen SEW

Blood 143 (11) 953-966 [2024-03-14; online 2023-12-14]

NGI Short read [Service] NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]

Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts.

Todisco G, Creignou M, Bernard E, ..., Papaemmanuil E, Hellström-Lindberg E

Clin. Cancer Res. 29 (20) 4256-4267 [2023-10-13; online 2023-07-27]

Bioinformatics Support for Computational Resources [Service] Bioinformatics Support, Infrastructure and Training [Collaborative]

Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

Jädersten M, Boriskina K, Lindholm C, ..., Mielke S, Tobiasson M

Leuk. Lymphoma - (-) 1-4 [2021-11-15; online 2021-11-15]

Clinical Genomics Uppsala [Collaborative]

Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.

Tobiasson M, Pandzic T, Cavelier L, Sander B, Wahlin BE

Leuk. Lymphoma 60 (13) 3316-3319 [2019-12-00; online 2019-06-17]

Clinical Genomics Uppsala [Collaborative]